Teleflex (TFX) Is Up 6.5% After Issuing 2026 Guidance Amid Widened Net Losses – What’s Changed

• Teleflex Incorporated recently reported fourth-quarter and full-year 2025 results showing higher sales of US$568.98 million for the quarter and US$1.99 billion for the year, alongside a widened net loss of US$714.33 million for the quarter and US$905.64 million for the year, while affirming a quarterly dividend of US$0.34 per share payable on March 31, 2026.
• At the same time, management issued 2026 guidance calling for revenue of US$2.28–US$2.30 billion and diluted earnings per share from continuing operations of US$2.90–US$3.20, highlighting a contrast between reported net losses and expectations for earnings from the ongoing core business.
• Now we’ll examine how Teleflex’s 2026 earnings guidance, issued alongside these results, affects the existing investment narrative for the company.

We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Teleflex Investment Narrative Recap

To own Teleflex, you need to believe its core medical device franchises and the BIOTRONIK vascular portfolio can translate higher sales into sustainable, recurring earnings despite recent headline losses. The 2026 guidance for earnings from continuing operations partially offsets concerns from the widened 2025 net loss, but integration execution and margin pressure remain the key near term catalyst and risk. The latest results do not remove those risks, but they do clarify where management thinks the underlying business is heading.

The most relevant update here is Teleflex’s 2026 guidance for revenue of US$2.28–US$2.30 billion and diluted EPS from continuing operations of US$2.90–US$3.20. This sits alongside a steady US$0.34 quarterly dividend, which suggests management is trying to signal confidence in the cash generating power of the ongoing business while investors weigh integration risk, pricing pressure and the gap between accounting losses and operating earnings.

Yet investors should be aware that pricing pressure and volume based procurement could still...

Read the full narrative on Teleflex (it's free!)

Teleflex's narrative projects $3.9 billion revenue and $553.0 million earnings by 2028.

Uncover how Teleflex's forecasts yield a $129.25 fair value, a 8% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were expecting Teleflex to reach about US$4.2 billion in revenue and US$675.6 million in earnings by 2028, which is far more upbeat than the consensus view. If you worry about pricing pressure in China and other markets, this new guidance and the large 2025 loss may prompt you to question whether that bullish path still holds, so it is worth comparing these different scenarios before deciding what you believe.

Explore 4 other fair value estimates on Teleflex - why the stock might be worth 40% less than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Teleflex research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Teleflex research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Teleflex's overall financial health at a glance.

Looking For Alternative Opportunities?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 21 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com